KR20180010345A - 면역억제성 수지상 세포를 얻는 방법 - Google Patents
면역억제성 수지상 세포를 얻는 방법 Download PDFInfo
- Publication number
- KR20180010345A KR20180010345A KR1020187002019A KR20187002019A KR20180010345A KR 20180010345 A KR20180010345 A KR 20180010345A KR 1020187002019 A KR1020187002019 A KR 1020187002019A KR 20187002019 A KR20187002019 A KR 20187002019A KR 20180010345 A KR20180010345 A KR 20180010345A
- Authority
- KR
- South Korea
- Prior art keywords
- mammalian subject
- monocytes
- platelets
- dendritic cells
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361748550P | 2013-01-03 | 2013-01-03 | |
| GB1300052.6 | 2013-01-03 | ||
| US61/748,550 | 2013-01-03 | ||
| GBGB1300052.6A GB201300052D0 (en) | 2013-01-03 | 2013-01-03 | Method for obtaining immuno-suppressive dendritic cells |
| PCT/EP2014/050012 WO2014106631A1 (en) | 2013-01-03 | 2014-01-02 | Method for obtaining immuno-suppressive dendritic cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157020667A Division KR20150122639A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207025108A Division KR20200106217A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180010345A true KR20180010345A (ko) | 2018-01-30 |
Family
ID=47747914
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187002019A Ceased KR20180010345A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
| KR1020157020667A Ceased KR20150122639A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
| KR1020207025108A Ceased KR20200106217A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157020667A Ceased KR20150122639A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
| KR1020207025108A Ceased KR20200106217A (ko) | 2013-01-03 | 2014-01-02 | 면역억제성 수지상 세포를 얻는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160130552A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3719118A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2016509474A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20180010345A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104955940A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014204346B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2897113C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2941484T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2795927T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201300052D0 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2941484T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014106631A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| US10124336B2 (en) | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| GB201413665D0 (en) * | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| CN122564053A (zh) | 2014-10-31 | 2026-08-14 | 麻省理工学院 | 递送生物分子至免疫细胞 |
| WO2016077761A1 (en) | 2014-11-14 | 2016-05-19 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| GB201513278D0 (en) * | 2015-07-03 | 2015-09-09 | Transimmune Ag And Yale University | Device and method for obtaining immunostimulatory antigen-presenting cells |
| JP6925984B2 (ja) | 2015-07-09 | 2021-08-25 | マサチューセッツ インスティテュート オブ テクノロジー | 無核細胞への物質の送達 |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| EP3518942A4 (en) * | 2016-09-29 | 2020-05-27 | Hadasit Medical Research Services&Development Ltd. | DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109701019B (zh) * | 2019-01-04 | 2021-07-16 | 中国人民解放军第二军医大学 | 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途 |
| BR112021013193A2 (pt) | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
| KR102904431B1 (ko) * | 2021-05-07 | 2025-12-26 | (주)나노팬텍 | 수지상 세포의 배양 방법 |
| WO2023283514A1 (en) * | 2021-07-06 | 2023-01-12 | Vanderbilt University | Fluid shear stress for ex vivo activation of immune effector cells |
| EP4376860A1 (en) | 2021-07-29 | 2024-06-05 | Transimmune AG | Methods for selectively reducing immunogenicity in a transplant |
| US20250375477A1 (en) * | 2021-07-29 | 2025-12-11 | Transimmune Ag | Selective tolerization - methods of selectively generating tolerogenic dendritic cells |
| CN121335708A (zh) | 2023-05-01 | 2026-01-13 | 耶鲁大学 | 用于疫苗接种的抗原特异性生理性树突状细胞 |
| JP2026516460A (ja) | 2023-05-01 | 2026-05-25 | エール・ユニバーシティ | 療法用の抗原特異的生理的樹状細胞 |
| CN118256609B (zh) * | 2024-02-06 | 2024-08-30 | 湖北文理学院 | Tm9sf1标志物在监测自身免疫性疾病病程中的应用 |
| WO2026074195A1 (en) | 2024-10-05 | 2026-04-09 | Yale University | Cytokine loaded activated dendritic cells |
| WO2026074196A1 (en) | 2024-10-05 | 2026-04-09 | Yale University | Checkpoint inhibitor loaded activated dendritic cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000062818A1 (en) | 1999-04-20 | 2000-10-26 | Richard Leslie Edelson | Differentiation of monocytes into functional dendritic cells |
| US8524495B2 (en) * | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| EP2358739A1 (en) * | 2008-11-18 | 2011-08-24 | The University Of Queensland | Peptide conjugates for suppressing an immune response, methods of making and uses therefor |
-
2013
- 2013-01-03 GB GBGB1300052.6A patent/GB201300052D0/en not_active Ceased
-
2014
- 2014-01-02 KR KR1020187002019A patent/KR20180010345A/ko not_active Ceased
- 2014-01-02 CA CA2897113A patent/CA2897113C/en active Active
- 2014-01-02 AU AU2014204346A patent/AU2014204346B2/en active Active
- 2014-01-02 KR KR1020157020667A patent/KR20150122639A/ko not_active Ceased
- 2014-01-02 ES ES14700050T patent/ES2795927T3/es active Active
- 2014-01-02 US US14/759,016 patent/US20160130552A1/en not_active Abandoned
- 2014-01-02 WO PCT/EP2014/050012 patent/WO2014106631A1/en not_active Ceased
- 2014-01-02 DK DK14700050.9T patent/DK2941484T3/da active
- 2014-01-02 KR KR1020207025108A patent/KR20200106217A/ko not_active Ceased
- 2014-01-02 CN CN201480003942.3A patent/CN104955940A/zh active Pending
- 2014-01-02 EP EP20160436.0A patent/EP3719118A1/en active Pending
- 2014-01-02 PL PL14700050T patent/PL2941484T3/pl unknown
- 2014-01-02 CN CN202111008277.5A patent/CN114410581A/zh active Pending
- 2014-01-02 EP EP14700050.9A patent/EP2941484B1/en active Active
- 2014-01-02 JP JP2015551179A patent/JP2016509474A/ja active Pending
-
2017
- 2017-10-25 JP JP2017205758A patent/JP6599958B2/ja active Active
-
2019
- 2019-10-03 JP JP2019182703A patent/JP6804607B2/ja active Active
-
2021
- 2021-10-21 US US17/507,002 patent/US20220259556A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB201300052D0 (en) | 2013-02-20 |
| AU2014204346B2 (en) | 2017-08-31 |
| EP2941484B1 (en) | 2020-03-04 |
| JP2018046837A (ja) | 2018-03-29 |
| US20160130552A1 (en) | 2016-05-12 |
| JP6599958B2 (ja) | 2019-10-30 |
| JP2016509474A (ja) | 2016-03-31 |
| HK1210626A1 (en) | 2016-04-29 |
| CA2897113C (en) | 2024-03-12 |
| PL2941484T3 (pl) | 2020-10-05 |
| US20220259556A1 (en) | 2022-08-18 |
| CN104955940A (zh) | 2015-09-30 |
| JP6804607B2 (ja) | 2020-12-23 |
| ES2795927T3 (es) | 2020-11-25 |
| KR20150122639A (ko) | 2015-11-02 |
| DK2941484T3 (da) | 2020-06-02 |
| JP2020018315A (ja) | 2020-02-06 |
| EP2941484A1 (en) | 2015-11-11 |
| WO2014106631A1 (en) | 2014-07-10 |
| CA2897113A1 (en) | 2014-07-10 |
| CN114410581A (zh) | 2022-04-29 |
| AU2014204346A1 (en) | 2015-07-02 |
| KR20200106217A (ko) | 2020-09-11 |
| EP3719118A1 (en) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102362647B1 (ko) | 전반적으로 활성화된 단핵구를 수득하는 방법 | |
| AU2020270508B2 (en) | C/EBP alpha short activating RNA compositions and methods of use | |
| KR20180128993A (ko) | 면역자극성 수지상 세포를 얻는 방법 | |
| KR20200106217A (ko) | 면역억제성 수지상 세포를 얻는 방법 | |
| AU2017267184B2 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
| CN114176043B (zh) | 用于治疗疾病的遗传修饰的细胞、组织和器官 | |
| KR102301464B1 (ko) | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 | |
| ES2744098T3 (es) | Composiciones y sus usos dirigidos a la huntingtina | |
| KR20210138587A (ko) | 개선된 면역요법을 위한 조합 유전자 표적 | |
| KR102149483B1 (ko) | 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도 | |
| KR20230034198A (ko) | 종양 침윤 림프구의 활성화 및 확장 방법 | |
| KR102424991B1 (ko) | 타우 발현 조절 조성물 | |
| CN115003387A (zh) | 用于活化和扩增肿瘤浸润淋巴细胞的方法 | |
| AU2016364667A1 (en) | Materials and methods for treatment of Alpha-1 antitrypsin deficiency | |
| KR20120082906A (ko) | 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법 | |
| KR20170092692A (ko) | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 | |
| KR20160027968A (ko) | Foxp3 발현을 조절하기 위한 조성물 및 방법 | |
| KR20220012230A (ko) | 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물 | |
| KR20040065524A (ko) | 백혈병을 검사 및 치료하는 방법 | |
| KR20250021378A (ko) | 단일유전자성 신경발달 장애 치료를 위한 조성물 및 방법 | |
| US20020137077A1 (en) | Genes regulated in activated T cells | |
| US12478665B2 (en) | Cancer vaccine compositions and methods for using same to prevent and/or treat cancer | |
| KR20190126812A (ko) | 질환 진단용 바이오마커 | |
| CN100516876C (zh) | 用于诊断肾细胞癌(rcc)和其他实体瘤的方法 | |
| WO2025260064A1 (en) | Gene targets discovered through in vivo crispr activation screens to improve t cell products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PX0601 | Decision of rejection after re-examination |
St.27 status event code: N-2-6-B10-B17-rex-PX0601 |
|
| X601 | Decision of rejection after re-examination | ||
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |